RxDoctor Payments Data

Kimberly Belzer, PA

Medical · Detroit, MINPI 1730126731

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,570 of the $16,259 with a category attached, or 65.0%. Jazz Pharmaceuticals Inc. accounts for 79.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $6,806, more than ten times the $127 reported in 2021. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,259in general payments, 2019–2025

Across 47 payments — averaging $345.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$13K
  • Janssen Scientific Affairs, LLC$3K
  • Amgen$252
  • E.r. Squibb & Sons, L.L.C.$235
  • Takeda Pharmaceuticals U.S.A., Inc.$110
  • Regeneron Healthcare Solutions, Inc.$100
  • plus $96 from 3 others

What the payments were for

  • Consulting fees$2,25014%
  • Speaking & faculty fees$10,57065%
  • Travel & lodging$1,2728%
  • Food & beverage$2,16713%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,259 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$3,601
Medicare patients
25
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate68$1,092,020
LumakrasSotorasib23$460,493
LorbrenaLorlatinib14$263,564
EliquisApixaban38$24,300
Erlotinib Hcl17$2,754
Albuterol Sulfate HfaAlbuterol Sulfate23$738
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$466
Prochlorperazine Maleate24$402
Olanzapine20$105
Prednisone30$41
Famotidine17$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenLumakras$252$460,49323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.

Other medical in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →